Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable ...

BEIJING, Apr. 18 (China Economic Net) - China’s brain-computer interface (BCI) industry is moving into a new stage of development, as policymakers, hospitals, and companies seek to translate years of ...